Dec 08, 2022 10:32 AM (GMT+8) · EqualOcean
GenAssist (Chinese: 新芽基因), a gene-editing drug developer, announced that it had completed a Series A funding round worth tens of millions of USD. AstraZeneca-CICC Healthcare Industrial Fund (Chinese: 阿斯利康中金医疗产业基金) led this round, followed by Baidu Ventures (Chinese: 百度风投) and a well-known equity investment. Existing shareholder Sequoia Capital China (Chinese: 红杉中国) continued to invest. Taihecap (Chinese: 泰合资本) served as the exclusive financial advisor. Founded in 2020, GenAssist is committed to developing gene-editing drugs for various genetic diseases based on TAM (Targeted AID-based Mutagenesis) base editing technology platform. The funds will advance preclinical studies, IND filings, and clinical trials of the company's several base editing therapeutic pipelines.

Source: